Key Highlights
- AstraZeneca (LSE:AZN) has rarely had a busier fortnight. On 4 September 2026 the US Food and Drug Administration granted Accelerated Approval to ETCAMAH (camizestrant), the oral oestrogen receptor degrader underpinning much of the group's breast cancer ambition.
- For the six months to 30 June 2026, total Revenue reached $30,672m, up 9% at actual rates and 6% at constant exchange rates (CER). Core operating profit rose 11% at CER to about $10.5bn, lifting the core Operating Margin to 34%.
- AstraZeneca declared a first Interim Dividend for 2026 of $1.06 per share (79.5 pence; SEK 10.32), three cents higher than a year earlier. The shares went ex-dividend on 6 August 2026 in London and Stockholm, with a Record Date of 7 August and payment on 8 September 2026.
- China is the clearest pressure point, where volume-based procurement and generic competition drove the 5% CER decline. Farxiga fell 11% to $4,042m as US exclusivity lapsed, Brilinta dropped 66% and infectious disease revenue fell 26%.
- AstraZeneca enters the autumn with oncology compounding and rare disease steady, set against China weakness and Farxiga erosion.
Why AstraZeneca Is Commanding Attention Again
AstraZeneca (LSE:AZN) has rarely had a busier fortnight. On 4 September 2026 the US Food and Drug Administration granted accelerated approval to ETCAMAH (camizestrant), the oral oestrogen receptor degrader underpinning much of the group's breast cancer ambition. Three days earlier the European Commission cleared Enhertu plus pertuzumab as a first-line regimen in HER2-positive metastatic breast cancer, and AstraZeneca completed a $600m upfront licence for the lung cancer medicine ZEGFROVY (sunvozertinib) from China's Dizal Pharmaceutical. All of this follows half-year results showing oncology revenue up 15% at constant exchange rates. Add a rewired share listing spanning London, Stockholm and New York, and AZN is one of the more eventful large caps on the UK market. Shares traded at about 11,612p on the morning of 11 September 2026, valuing the group near £180bn (Yahoo Finance).
Latest Developments: Approvals Arriving in Clusters
The camizestrant approval rests on the Phase III SERENA-6 trial, in which the drug plus a CDK4/6 inhibitor cut the risk of disease progression or death by 56% versus an aromatase inhibitor plus CDK4/6 inhibitor, with median progression-free survival of 16.0 months against 9.2 months. Treatment is switched when an ESR1 mutation is detected in blood, before the cancer visibly progresses. The Enhertu decision, based on DESTINY-Breast09, showed a 44% reduction in the risk of progression or death and median progression-free survival of 40.7 months versus 26.9 months. Datroway, the TROP2 antibody-drug conjugate partnered with Daiichi Sankyo, won European approval on 31 July 2026 in first-line metastatic triple-negative breast cancer. Imfinzi added a US approval in non-muscle-invasive bladder cancer, and baxdrostat was cleared by the FDA in May 2026 as BAXFENDY.
H1 2026 Results: Revenue of $30.7bn and Core EPS Up 11%
For the six months to 30 June 2026, total revenue reached $30,672m, up 9% at actual rates and 6% at constant exchange rates (CER). Core operating profit rose 11% at CER to about $10.5bn, lifting the core operating margin to 34%. Core Earnings Per Share were $5.21, up 11% at CER; reported EPS was $3.60.
Chief executive Pascal Soriot said the company had delivered "strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets".
By therapy area, oncology generated $14,124m (up 15% at CER) and rare disease $4,911m (up 11%). BioPharmaceuticals fell 5% to $11,151m: respiratory and immunology grew 9%, but cardiovascular, renal and metabolism dropped 12%. Regionally, US revenue rose 8% to $12,890m, Europe 8% at CER to $6,822m and emerging markets excluding China 10% at CER to $4,809m, while China slipped 5% at CER to $3,510m. Net Debt stood at $26.9bn, with half-year Capital Expenditure of $1,513m set to rise by roughly a third across 2026.
Key Growth Drivers: Cancer Franchises and a Cardiometabolic Second Act
Imfinzi ($3,548m, up 29%), Calquence ($1,944m, up 16%), Enhertu ($1,719m, up 32%) and Truqap ($431m, up 41%) supplied most of the oncology momentum, with Tagrisso still the largest single medicine at $3,775m. Datroway remains early, at $98m; in rare disease, Ultomiris reached $2,584m, up 14%.
Management is also building an obesity and cardiometabolic franchise. On the July results call, AstraZeneca said its oral GLP-1 candidate elecoglipron produced weight loss of up to 11.8% at week 36 in Phase IIb, with Phase III dosing starting in July 2026; a Phase III monotherapy trial of the amylin agonist AZD6234 has begun, and first Phase III data for an oral PCSK9 inhibitor are expected in the first half of 2027.
Guidance and the $80bn Ambition
AstraZeneca reconfirmed full-year 2026 guidance for total revenue growth of a mid-to-high single-digit percentage and core EPS growth of a low double-digit percentage, both at CER, with a core tax rate of 18–22%. These are forward-looking targets, not outcomes. The group also reiterated its $80bn total revenue ambition for 2030, describing it as Risk-adjusted and not dependent on M&A; FY2025 revenue was $58,739m. The supporting pipeline contains 183 projects, including 116 new molecular entities or major life-cycle programmes in Phase II or III, with more than 20 high-value readouts flagged over the next 18 months.
US Listing, Tariffs and Washington
On 2 February 2026 AstraZeneca implemented a harmonised listing structure: ordinary shares now trade directly on the New York Stock Exchange alongside London and Nasdaq Stockholm, the American Depositary Receipt Facility has closed, and the ticker remains AZN on all three exchanges, with the ISIN unchanged. AZN remains a FTSE 100 constituent.
On policy, the 2025 Annual Report states that in October 2025 the company "announced an agreement with the US administration which provides greater clarity around pricing and a three-year exemption from tariffs". AstraZeneca has committed $50bn of US investment, including a $4.5bn Virginia Manufacturing site and about $2bn in Maryland. The Q1 2026 announcement listed implementation of that agreement among factors affecting gross margin, a reminder that the pricing side carries a cost.
Dividends and Share Buybacks
AstraZeneca declared a first interim dividend for 2026 of $1.06 per share (79.5 pence; SEK 10.32), three cents higher than a year earlier. The shares went ex-dividend on 6 August 2026 in London and Stockholm, with a record date of 7 August and payment on 8 September 2026. At the FY2025 results the board said it intends to raise the annual dividend declared to $3.30 per share in FY2026; the FY2025 second interim alone was $2.17. No share buyback programme was disclosed in the FY2025, Q1 2026 or H1 2026 announcements.
Risks and Challenges
China is the clearest pressure point, where volume-based procurement and generic competition drove the 5% CER decline. Farxiga fell 11% to $4,042m as US exclusivity lapsed, Brilinta dropped 66% and infectious disease revenue fell 26%. Rising capital expenditure and net debt of $26.9bn reduce flexibility, and the US Tariff exemption runs for three years rather than indefinitely. A pipeline-led story is also exposed to trial failure: several coming readouts are material to the 2030 ambition.
What Investors May Watch Next
The SERENA-4 readout for camizestrant in the first-line setting is due in the second half of 2026, and AVANZAR will test Datroway in lung cancer. ESMO 2026 is the next major data venue, and the US launch of ZEGFROVY is planned for the fourth quarter. Investors will also watch for signs that China stabilises and that third-quarter results keep guidance intact.
Conclusion
AstraZeneca enters the autumn with oncology compounding and rare disease steady, set against China weakness and Farxiga erosion. Oncology progress and pipeline depth are borne out by the H1 2026 numbers; delivery over the coming 18 months of readouts will decide whether the $80bn ambition looks conservative or stretched.






Please wait processing your request...